Acquisition of the L452R Mutation in the ACE2-Binding Interface of Spike Protein Triggers Recent Massive Expansion of SARS-CoV-2 Variants
- PMID: 34379531
- PMCID: PMC8525575
- DOI: 10.1128/JCM.00921-21
Acquisition of the L452R Mutation in the ACE2-Binding Interface of Spike Protein Triggers Recent Massive Expansion of SARS-CoV-2 Variants
Abstract
We report that there is a recent global expansion of numerous independent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with mutation L452R in the receptor-binding domain (RBD) of the spike protein. The massive emergence of L452R variants was first linked to lineage B.1.427/B.1.429 (clade 21C) that has been spreading in California since November and December 2020, originally named CAL.20C and currently variant of interest epsilon. By PCR amplification and Sanger sequencing of a 541-base fragment coding for amino acids 414 to 583 of the RBD from a collection of clinical specimens, we identified a separate L452R variant that also recently emerged in California but derives from the lineage B.1.232, clade 20A (named CAL.20A). Notably, CAL.20A caused an infection in gorillas in the San Diego Zoo, reported in January 2021. Unlike the epsilon variant that carries two additional mutations in the N-terminal domain of spike protein, L452R is the only mutation found in the spike proteins of CAL.20A. Based on genome-wide phylogenetic analysis, emergence of both viral variants was specifically triggered by acquisition of L452R, suggesting a strong positive selection for this mutation. Global analysis revealed that L452R is nearly omnipresent in a dozen independently emerged lineages, including the most recent variants of concern/interest delta, kappa, epsilon and iota, with the lambda variant carrying L452Q. L452 is in immediate proximity to the angiotensin-converting enzyme 2 (ACE2) interaction interface of RBD. It was reported that the L452R mutation is associated with immune escape and could result in a stronger cell attachment of the virus, with both factors likely increasing viral transmissibility, infectivity, and pathogenicity.
Keywords: L452R; SARS-CoV-2; expansion; mutation.
Figures
Update of
-
Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-Cov-2 variants.bioRxiv [Preprint]. 2021 Mar 11:2021.02.22.432189. doi: 10.1101/2021.02.22.432189. bioRxiv. 2021. PMID: 33758861 Free PMC article. Updated. Preprint.
Similar articles
-
Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-Cov-2 variants.bioRxiv [Preprint]. 2021 Mar 11:2021.02.22.432189. doi: 10.1101/2021.02.22.432189. bioRxiv. 2021. PMID: 33758861 Free PMC article. Updated. Preprint.
-
Emerging Variants of SARS-CoV-2 and Novel Therapeutics Against Coronavirus (COVID-19).2023 May 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 May 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 34033342 Free Books & Documents.
-
V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.J Virol. 2021 Jul 26;95(16):e0061721. doi: 10.1128/JVI.00617-21. Epub 2021 Jul 26. J Virol. 2021. PMID: 34105996 Free PMC article.
-
SARS-CoV-2's Variants of Concern: A Brief Characterization.Front Immunol. 2022 Jul 26;13:834098. doi: 10.3389/fimmu.2022.834098. eCollection 2022. Front Immunol. 2022. PMID: 35958548 Free PMC article. Review.
-
Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.Front Immunol. 2021 Dec 22;12:732690. doi: 10.3389/fimmu.2021.732690. eCollection 2021. Front Immunol. 2021. PMID: 35003058 Free PMC article. Review.
Cited by
-
Genomic characterization of SARS-CoV-2 in Guinea, West Africa.PLoS One. 2024 Mar 6;19(3):e0299082. doi: 10.1371/journal.pone.0299082. eCollection 2024. PLoS One. 2024. PMID: 38446806 Free PMC article.
-
Within-host evolution of SARS-CoV-2: how often are de novo mutations transmitted from symptomatic infections?Virus Evol. 2024 Feb 21;10(1):veae006. doi: 10.1093/ve/veae006. eCollection 2024. Virus Evol. 2024. PMID: 38425472 Free PMC article.
-
Challenges in Emerging Vaccines and Future Promising Candidates against SARS-CoV-2 Variants.J Immunol Res. 2024 Jan 25;2024:9125398. doi: 10.1155/2024/9125398. eCollection 2024. J Immunol Res. 2024. PMID: 38304142 Free PMC article. Review.
-
Deciphering the rule of antigen-antibody amino acid interaction.Front Immunol. 2023 Dec 4;14:1269916. doi: 10.3389/fimmu.2023.1269916. eCollection 2023. Front Immunol. 2023. PMID: 38111576 Free PMC article.
-
Genomic Characterization of an Emerging SARS-CoV-2 Variant During the Early Second Wave of the SARS-CoV-2 Pandemic in Maharashtra, India.Cureus. 2023 Nov 10;15(11):e48604. doi: 10.7759/cureus.48604. eCollection 2023 Nov. Cureus. 2023. PMID: 38090396 Free PMC article.
References
-
- Flores-Alanis A, Cruz-Rangel A, Rodriguez-Gomez F, Gonzalez J, Torres-Guerrero CA, Delgado G, Cravioto A, Morales-Espinosa R. 2021. Molecular epidemiology surveillance of SARS-CoV-2: mutations and genetic diversity one year after emerging. Pathogens 10:184. 10.3390/pathogens10020184. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
